Primary Analysis News Today

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

But where mosunetuzumab/polatuzumab vedotin would fit among available options remains a question

Foods for your baby need to contain different nutrients for its growth and development. Know different forms in which foods can be introduced and enjoyed.

Investegate announcements from F. Hoffmann-La Roche Ltd, European Commission approves label expansion of Roche’s Hemlibra to include people with moderate haemophilia A in the EU

Investegate announcements from F. Hoffmann-La Roche Ltd, CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A

Trial met its primary endpoint, with 64.3% of patients receiving etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR =...

November 4, 2022—Five-year results of the LEOPARD trial demonstrated that the AFX2 anatomically fixated endograft (Endologix LLC) has similar ou

/PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...

/PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...

The American Heart Association (AHA) Scientific Sessions 2022 in Chicago, and virtually, is set for November 5-7 at McCormick Place. Highly-anticipated clinical trial breakthroughs and discoveries of the year will be offered in both late-breaking scientific sessions and featured science sessions.